Trulicity (Dulaglutide) in Children Under 12: Off-Label Use, Evidence, and Clinical Guidance

What Is Dulaglutide and Why Might It Be Considered in Young Children?

Dulaglutide is a once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA to improve glycemic control in adults with type 2 diabetes and, since 2020, in pediatric patients aged 10 and older [1]. It works by binding GLP-1 receptors in the pancreas to stimulate glucose-dependent insulin release, suppress glucagon, slow gastric emptying, and reduce appetite [2].

The Approved Indication Does Not Cover Children Under 10

The FDA label for Trulicity explicitly lists the minimum age as 10 years for the type 2 diabetes indication [1]. No approved indication exists for obesity, metabolic syndrome, or prediabetes in any pediatric age group as of 2025. A child aged 9 or younger who receives dulaglutide is receiving it outside the scope of every current labeling statement.

Why the Question Arises

Type 2 diabetes in children under 10 is rare but documented. The CDC estimates that roughly 1.87 per 100,000 children aged 10 to 19 carry a type 2 diabetes diagnosis, with rates lower still in younger cohorts [3]. Severe early-onset obesity also drives clinician inquiry. When lifestyle intervention and metformin fail in a child younger than 10, providers occasionally ask whether GLP-1 agents offer an alternative. The honest answer is that the evidence does not yet support a confident yes.

FDA Approval Status and the Regulatory Pathway to the 10-Year Age Limit

How the 2020 Pediatric Approval Was Granted

The FDA extended dulaglutide's approval to patients aged 10 and older in June 2020 based on the AWARD-PEDS trial [4]. That randomized, double-blind, Phase 3 study enrolled 154 pediatric participants aged 10 to 17 with type 2 diabetes. At 26 weeks, dulaglutide 0.75 mg reduced HbA1c by 0.6 percentage points versus a 0.5 percentage-point rise in the placebo group (treatment difference: 1.1 percentage points; P<0.001) [4]. No children under 10 were enrolled, which is why the label stops at age 10.

The Pediatric Research Equity Act

Under the Pediatric Research Equity Act (PREA), the FDA may require manufacturers to study drugs in pediatric subgroups [5]. Eli Lilly was not required to conduct studies in children under 10 for the type 2 diabetes indication because the disease prevalence in that age group does not meet the threshold that triggers a mandatory study requirement. This regulatory gap leaves clinicians without manufacturer-generated data for younger children.

Off-Label Prescribing: Legal but Unvalidated

Physicians in the United States may legally prescribe any approved drug off-label. The FDA does not prohibit this practice [6]. However, prescribing dulaglutide to a child under 10 means using a drug in a population for whom no pharmacokinetic data, no dose-ranging study, and no safety surveillance program exists beyond spontaneous adverse event reporting.

Evidence Base: What the Trials Actually Show

AWARD-PEDS (Ages 10 to 17)

AWARD-PEDS is the only Phase 3 controlled trial of dulaglutide in pediatric patients [4]. It enrolled 154 participants (mean age 14.0 years; 62% female; mean baseline HbA1c 8.0%) and randomized them to dulaglutide 0.75 mg weekly, dulaglutide 1.5 mg weekly, or placebo for 26 weeks, followed by an open-label extension. The 1.5 mg dose reduced HbA1c by 0.9 percentage points versus placebo at 26 weeks. Gastrointestinal adverse events (nausea, vomiting, diarrhea) were reported in approximately 30% of dulaglutide recipients versus 19% in placebo. No pediatric participants under age 10 were enrolled, so extrapolating these results to younger children is not supported by the data.

Liraglutide Data in Children 10 and Older: Limited Generalizability

The ELLIPSE trial (NCT01776918) tested liraglutide in children aged 10 to 17 with type 2 diabetes and showed a 1.06 percentage-point HbA1c reduction versus 0.50 percentage points for placebo at 26 weeks [7]. Liraglutide carries its own separate FDA approval for this age group. Neither this trial nor the AWARD-PEDS data provides a physiological rationale to assume equivalent outcomes in children aged 6 to 9.

Semaglutide in Adolescents: The STEP TEENS Trial

The STEP TEENS trial (N=201, ages 12 to 17) reported that once-weekly semaglutide 2.4 mg reduced BMI by 16.1% versus a 0.6% reduction with placebo over 68 weeks (P<0.001) [8]. This is relevant context because it shows GLP-1 agents can produce meaningful metabolic effects in adolescents, but STEP TEENS enrolled no one under 12. The lower age boundary of published GLP-1 obesity data does not extend to children under 10.

Pharmacokinetic Extrapolation Gaps

Adult and adolescent pharmacokinetic data for dulaglutide show a half-life of approximately 5 days, with steady-state reached after 2 to 4 weeks of weekly dosing [2]. Body weight, renal maturation, and hepatic enzyme activity all differ substantially in children under 6 compared with 10-year-olds [9]. No published pharmacokinetic modeling study has formally characterized expected dulaglutide exposures in children under 10, and no dose-adjustment algorithm exists for this group.

Safety Considerations Specific to Young Children

Gastrointestinal Toxicity in a Developing Gut

In AWARD-PEDS, nausea was the most common treatment-emergent adverse event at roughly 16% in the 0.75 mg arm [4]. Vomiting and diarrhea each occurred in approximately 10% of participants. Young children, particularly those under 6, have smaller gastric volumes and higher caloric density requirements per kilogram than adolescents. Persistent nausea or vomiting in this group carries a higher risk of growth faltering and micronutrient depletion than in older patients [10].

Risk of Hypoglycemia

Because dulaglutide stimulates insulin secretion in a glucose-dependent manner, isolated hypoglycemia is uncommon when the drug is used without sulfonylureas or insulin [2]. In AWARD-PEDS, severe hypoglycemia occurred in less than 2% of participants on dulaglutide monotherapy. Young children may be less able to recognize or verbalize hypoglycemic symptoms, which increases the monitoring burden on caregivers.

Rodent Thyroid C-Cell Findings and the MTC Warning

The FDA black-box warning for all GLP-1 receptor agonists, including dulaglutide, references dose-dependent and duration-dependent thyroid C-cell tumors observed in rodent studies [1]. Human relevance has not been established, but the FDA requires that dulaglutide be contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN2) [1]. Genetic testing for MEN2 mutations before initiating any off-label GLP-1 therapy in a young child is a reasonable precaution.

Pancreatitis

Acute pancreatitis has been reported post-marketing with GLP-1 receptor agonists [1]. The absolute risk appears low, but pancreatitis in young children carries a higher complication rate than in adults [11]. Baseline amylase and lipase measurement before starting, and a clear plan for symptom monitoring, are standard precautions in this population.

Current Guideline Positions

ADA Standards of Medical Care 2025

The American Diabetes Association (ADA) 2025 Standards of Medical Care in Diabetes state that GLP-1 receptor agonists approved for pediatric use (liraglutide and dulaglutide) may be considered as adjunctive therapy in patients aged 10 and older after metformin and lifestyle therapy [12]. The ADA does not address use in children under 10 with type 2 diabetes because the evidence base does not exist for that cohort.

"For youth with type 2 diabetes aged 10 years and older who are not achieving glycemic targets with lifestyle and metformin, addition of a GLP-1 receptor agonist is recommended." (ADA Standards of Medical Care in Diabetes, 2025, Section 14) [12]

Endocrine Society and Pediatric Endocrine Society

The Pediatric Endocrine Society (PES) and the Endocrine Society have not issued a joint guideline specifically endorsing GLP-1 receptor agonist use in children under 10 for any indication as of mid-2025 [13]. Their obesity management guidelines for pediatric patients focus on behavioral intervention as first-line and pharmacotherapy as adjunctive, with age thresholds aligned to existing FDA approvals.

AAP Obesity Guidelines 2023

The American Academy of Pediatrics (AAP) 2023 Clinical Practice Guideline for Obesity in Children and Adolescents recommends intensive health behavior and lifestyle treatment as the foundational approach [14]. Pharmacotherapy is addressed for children aged 12 and older (for weight management), again reflecting the FDA approval field rather than a deliberate exclusion of younger children based on independent safety data.

The table below summarizes the current guideline age thresholds for GLP-1 use in pediatric patients. No guideline body currently endorses use below age 10.

| Guideline Body | Minimum Age for GLP-1 Use | Indication Covered | |---|---|---| | ADA 2025 | 10 years | Type 2 diabetes | | FDA Label (dulaglutide) | 10 years | Type 2 diabetes | | FDA Label (liraglutide) | 10 years | Type 2 diabetes | | FDA Label (semaglutide injection) | 12 years | Obesity (Wegovy) | | AAP 2023 | 12 years | Obesity | | Pediatric Endocrine Society | No stated threshold below 10 | No off-label recommendation |

Dosing Considerations If Off-Label Use Proceeds Under Specialist Supervision

No Validated Dosing Algorithm Exists

There is no published weight-based or age-based dosing algorithm for dulaglutide in children under 10. The lowest approved dose is 0.75 mg once weekly. Because no pharmacokinetic study has been conducted in children under 10, a clinician who decides to prescribe this drug in a younger child cannot rely on any validated calculation to determine a safe starting dose.

Practical Starting Points Used in Specialist Centers

Some pediatric endocrinologists, operating under close monitoring protocols, have initiated dulaglutide at the 0.75 mg once-weekly dose in children aged 8 to 9 with severe treatment-refractory type 2 diabetes. This practice is not codified in any published protocol, and published case series in children under 10 remain sparse [15]. Any such use should occur only within a structured clinical pathway that includes:

• Baseline HbA1c, fasting glucose, lipid panel, hepatic function tests, amylase, and lipase
• Weekly caregiver contact for the first four weeks to assess gastrointestinal tolerance
• Growth and weight monitoring at every visit
• A pre-defined stopping rule if weight-for-age falls below the 5th percentile or if pancreatitis symptoms develop

Titration and Monitoring Schedule

In AWARD-PEDS, dose escalation from 0.75 mg to 1.5 mg weekly was permitted after 4 weeks based on tolerability and glycemic response [4]. If a clinician applies this approach off-label to a younger child, a slower titration schedule (for example, 12 weeks at 0.75 mg before any escalation) and more frequent monitoring would be a conservative interpretation of the available adolescent data [9].

Informed Consent and Ethical Considerations

What Families Must Be Told

Prescribing an off-label medication to a child under 10 creates a heightened obligation for transparent informed consent. Families should be explicitly told that:

1. No clinical trial has tested this drug in children under 10.
2. The FDA has not approved this drug for this age group.
3. Long-term effects on growth, puberty, and neurodevelopment are unknown.
4. Alternative approved treatments (metformin, insulin, liraglutide at age 10) exist.

The FDA's guidance on off-label use emphasizes that informed consent discussions for pediatric patients should cover the absence of pediatric-specific data when such data do not exist [6].

Institutional Review and Compassionate Use

For children with severe early-onset type 2 diabetes unresponsive to metformin and insulin, some academic centers pursue institutional review board (IRB) oversight for off-label prescribing or enroll patients in investigator-initiated trials. This pathway provides a structured safety net and contributes to the evidence base that currently does not exist for children under 10.

Alternatives to Off-Label Dulaglutide in Children Under 10

Metformin: The First-Line Standard

Metformin is FDA-approved for children aged 10 and older for type 2 diabetes and is frequently used off-label in younger children with insulin resistance [16]. The drug's safety record in pediatric patients is longer and more strong than any GLP-1 agent. The TODAY trial (N=699) demonstrated that metformin monotherapy maintained glycemic targets in approximately 52% of youth with type 2 diabetes over a mean follow-up of 3.9 years [17].

Insulin

Insulin remains the backbone of glycemic management in children under 10 with type 2 diabetes who are not adequately controlled on metformin alone [12]. Its pharmacology is well-characterized across all pediatric age groups, and weight-based dosing algorithms are validated.

Liraglutide

Liraglutide (Victoza) carries FDA approval for type 2 diabetes in patients aged 10 and older and is available as a daily injection [7]. It is not approved below age 10 either, so it does not resolve the gap for children under that threshold. Its daily dosing may complicate adherence in young children compared with once-weekly dulaglutide.

Investigational Options and Active Trials

As of mid-2025, ClinicalTrials.gov lists several investigator-initiated studies examining GLP-1 agents in pediatric metabolic disease [18]. Referral to a center conducting such research is a legitimate clinical option for families seeking treatment that could also contribute to the evidence base.

What the Current Evidence Gaps Mean for Clinical Practice

The absence of trial data in children under 10 is not evidence of harm. However, it also cannot be treated as evidence of safety. GLP-1 receptors are expressed in the developing brain, gastrointestinal tract, and pancreas in ways that may differ meaningfully from adults [19]. The long-term consequences of GLP-1 receptor agonism during early childhood development have not been studied in humans.

Clinicians who encounter a child under 10 with type 2 diabetes refractory to metformin and insulin should first pursue a referral to a pediatric endocrinology center. If that center has the capacity for structured off-label use with IRB oversight, that pathway is preferable to community-level prescribing without a safety monitoring framework.

The ADA's position that GLP-1 agents may be used from age 10 onward provides a reasonable lower boundary below which caution should scale substantially [12]. A 9-year-old is physiologically closer to a 10-year-old than to a 5-year-old, and some clinicians weigh that proximity against the absence of formal data. A 5-year-old represents an entirely different developmental category for which no analogical reasoning from adolescent trials is defensible.

The FDA Adverse Event Reporting System (FAERS) contains a small number of pediatric dulaglutide reports in children under 10, though FAERS data cannot establish causality or incidence rates [20]. Spontaneous reporting underestimates true adverse event rates, particularly in populations where off-label use is not widely acknowledged.